Fennec Pharmaceuticals (FENC) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Fennec Pharmaceuticals (FENC) is Neutral.

The composite score behind that read is +0.01, weighing +0.09 of bullish evidence against -0.23 bearish.

Fennec Pharmaceuticals last closed at $10.71, +0.75% on the session.

Against the IVW growth benchmark the position is -0.05% over the forecast window.

The read is built from 15 underlying insights — 5 bullish and 10 bearish.

Agreement across those insights is 67%.

4 graded predictions for FENC so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Fennec Pharmaceuticals in the 17th percentile on return on equity, where 100 is best.

Fennec Pharmaceuticals is classified under Health Care / Biotechnology, with a market capitalisation of $372.67M.

StockMap tracks Fennec Pharmaceuticals as the 198th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Fennec Pharmaceuticals ranks 86th of 381 in the group, against a group median of -0.08.